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HAS BEHAVIORAL SCIENCE TUMBLED THROUGH THE BIOLOGICAL 
LOOKING GLASS? WILL BRIEF, EVIDENCE-BASED TRAINING 
RETURN IT FROM THE RABBIT HOLE? 
Donna M. Midkiff and W. Joseph Wyatt1 
Marshall University 
ABSTRACT: Time constraints and professional demands leave practicing professionals 
unlikely to enroll in extended training such as a semester-long graduate course. Thus, the 
three-hour continuing education format has become a standard for those in practice. One 
may ask what sorts of training strategies optimize that format. To explore that, a three-
hour training program for seventy-six practicing mental health professionals, most of 
whom self-identified as psychologists, was devised. It made use of primarily antecedent 
techniques that have been shown to bring about changed perceptions on a number of 
topics. Content focused on two areas of importance to behavior analysts, the culture’s 
increasing acceptance of the biological causation model of disorders such as attention-
deficit hyperactivity disorder (ADHD), unipolar depression, anxiety disorders, and 
schizophrenia, and the field’s increasing reliance on medications, often to the exclusion 
of behavioral methods. Pre-post assessment showed that participants had changed their 
thinking regarding the two content areas. The authors caution that participants’ changed 
opinions may serve as setting events to changes in practice, but those changes are verbal. 
One must not assume changes in practice techniques will automatically occur.  
KEYWORDS: brief training, continuing education, biological causation, biological 
psychiatry, pharmaceutical industry 
The shaping of opinions is of interest to those in both the behavioral sciences 
and clinical practice. What factors are involved when a professional’s opinion is 
changed regarding an important issue within the field? This study was an effort to 
explore that question by looking at professionals’ opinions regarding the causes of 
disorders and the factors that may change their thinking, within the context of 
what is arguably the most common format for ongoing training, a three-hour 
continuing education program. A timely topic was selected as content—the 
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mental health field’s increasing turn to biological explanations, and the co-
occurring rise of psychotropic medications as the treatment of choice. Some 
background on those issues is helpful. 
A Changed Cultural Worldview 
Clearly, a number of disorders such as dementias, Down’s syndrome, and 
disorders attributable to brain tumors, intracranial infection, and toxins are 
biologically caused. In contrast, the causes of other disorders, such as the majority 
of cases of depression, anxiety, attention-deficit hyperactivity disorder (ADHD) 
and schizophrenia often are unknown and likely vary from patient to patient. 
Adding to the difficulty in teasing out causes of the latter disorders is that some of 
them may be said to be the result of learning histories that act upon biological 
predispositions.  
It has been suggested that matters such as guild protectionism and economics 
have driven a preference for biological explanations of behavioral disorders in 
recent decades, and that both the professional and public communities are willing 
to endorse the biological model at levels of confidence that go well beyond the 
data (Terry & Kohlenberg, 2006; Valenstein, 1998; Winston, 2006; Wong, 2006a; 
Wong, 2006b; Wong, 2007; Wyatt, 2003; Wyatt, 2006; Wyatt & Midkiff, 2006a; 
Wyatt & Midkiff, 2006b; Wyatt & Midkiff, 2007). Many years ago, Skinner had 
observed the beginnings of this phenomenon when he coined the term 
“conceptual nervous system,” to point out that human biology had become a 
convenient “dumping ground” where the cause of any unexplained abnormal 
behavior is hypothesized to lie (Skinner, 1974, pp. 48-49). 
The biological worldview of common disorders such as depression and 
anxiety has strengthened in recent years, despite opinions that there exists 
relatively modest evidence to directly support it, at least for many cases of such 
disorders (Antonuccio, Danton, DeNelsky, Greenberg & Gordon, 1999; Wyatt, 
2003; Wyatt & Midkiff, 2006). Additionally, behaviors perhaps best thought of as 
natural reactions are now, at times, erroneously conceptualized as biological 
disorders (Horowitz & Wakefield, 2007). Moreover, it is clear that learning theory 
provides a plausible basis for the etiology and maintenance of many problems in 
functioning such as anxiety disorders and most child conduct problems (Mineka 
& Zinbarg, 2006) as well as for many cases of depression (Seligman, 1975; 
Abramson, Metalsky & Alloy, 1989) and other disorders. A more complete 
discussion of the debate may be found in special issues of Behavior and Social 
Issues (Special Issue: Mental Illness, Mental Health, and Cultural Analytic 
Science, 2006; Special Section: Behavior Analysis, Biological Determinism, and 
Biological Psychiatry, 2007).  
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Increasing medicalization of behavioral disorders may impede imple-
mentation of non-drug treatment. A new patient may come to therapy already 
convinced by advertising or the family doctor that his problems are genetic or 
chemical in nature, regardless of whether there is evidence to support that notion. 
The culture’s resulting preference for medications over other therapies is 
illustrated by recent studies. When parents were given a prescription for a drug 
and then told to also enroll their ADHD children in behavioral intervention 
programs, only twenty-five percent did so. In contrast, when parents were told by 
their doctors to first try behavioral interventions, ninety-five percent did so 
(Pelham, 2009). A 2001 to 2003 study of over 80,000 adults and 5,000 children 
by managed care tracker Medco Health Solutions found that in the three months 
following initial prescription of an antidepressant, more than three quarters of the 
adults and over half of the children had not had a mental health visit (Stettin, Yao, 
Verbrugge, & Aubert, 2006). 
In this atmosphere it is probable that, for many mental health professionals, 
there exist gaps between their acceptance of biological causation and the state of 
the research. A brief, data-based training program might bring about changes in 
their thinking. Because active professionals typically receive training in half-day 
or full-day continuing education programs, it is helpful to work within such time 
frames. However, research-based training of well-functioning individuals has 
typically targeted university students, parents of children with behavioral 
problems and caregivers for those with disabilities, rather than mental health 
professionals. Evidently little or no research has been conducted regarding world-
view change among practicing mental health professionals. 
Such professionals should be knowledgeable regarding a number of thorny 
issues. These include psychiatry’s shift to biological formulations of disorders, 
interpretation conundrums within family/genetic and brain function studies, 
disputed drug study methodology and questionable pharmaceutical industry 
marketing tactics. (See the special issues that are referenced above.) 
Training approaches 
A great deal has been written about educational practices that best bring 
about changes in beliefs, attitudes and opinions (e.g., Allen & Preiss, 1998; 
Cialdini, 2001; Dillard & Pfau, 2002; Perloff, 1993). The great majority of such 
studies have targeted individuals other than the mental health practitioners. For 
the most part, the literature has focused upon changing beliefs concerning 
political matters, consumer products and guilt or innocence of defendants in 
criminal and civil cases. There exists some behavioral literature on training well-
functioning adults. However, it often involves parent training or training 
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caregivers for the disabled, or it has focused on changing the classroom 
performance of university students over the course of a full academic semester 
(e.g., Ryan & Hemmes, 2005; Saville, Zinn, Neef, Van Norman, & Ferreri, 2006). 
An EBSCO host search revealed no results for “attitude change” or “opinion 
change” when these terms were combined with any of the following: mental 
health, schizophrenia, depression, anxiety or ADHD. Additional search of the 
literature uncovered no other relevant sources. 
Despite the lack of empirical evidence relative to the mental health field and 
attitude change, some fairly consistent findings have emerged regarding a number 
of variables that are thought to be influential in changing beliefs of listeners. For 
example, physical attractiveness of the speaker tends to exert a positive influence 
on message acceptance (e.g., Cialdini, 2001; Haughtvedt, 1997; Perloff, 1993). 
Similarly, perceived prestige of the speaker tends to enhance attitude change 
(Aronson & Golden, 1962; Berlo, Lemest, & Martin, 1969; Eagly, Wood, & 
Chaiken, 1978; Haughtvedt, 1997).  
A speaker’s verbal presentation style has impact upon the listener’s adoption 
of the speaker’s position. That is, a speaker’s verbal speed, intensity, choice of 
words and the like will influence the resulting level of agreement with the 
speaker’s position (Perloff, 1993). A review of the influence of verbal style 
revealed several factors that any speaker would do well to practice. An extensive 
vocabulary is beneficial; use of declaratives, as opposed to questions, results in 
greater attitude change; employment of empty adjectives (“cute,” “sweet”) 
degrades message acceptance as does being overly polite. The use of hedges (“I 
guess,” “kinda,” “you know”) and intensives (“very” and other superlatives) tends 
to hamper message acceptance, while use of powerful language (“it is,” and “no 
doubt”) adds credibility (Burrell & Koper,1998). 
Although historically audiences were thought to be passive, taking in 
whatever message was brought to them, that conceptualization has changed. In 
the past audiences were thought of as infused with information, much like a 
person is injected with medicine by means of a hypodermic syringe. In more 
recent years the theoretical position that audiences actively process information 
has taken root (Perloff, 1993). It is said that listeners may do this in either of two 
styles, systemic or heuristic, the latter also known as the elaboration likelihood 
model—ELM (e.g., Booth-Butterfield, 2005; Petty & Cacioppo, 1986). When a 
listener is responding systemically, he or she is actively involved, is alert, is 
attending to details and is weighing the content that is being presented. In 
contrast, when a listener is responding heuristically, he or she is more influenced 
by superficial variables such as physical attractiveness and verbal style. Although 
research continues along systemic/heuristic lines, it is clear from the host of 
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variables described above, that the interplay of listener style, speaker style and 
content is an area that has much to offer researchers in the field. 
Where the biological causation model of mental disorders is concerned, any 
effort to realign the attitudes and beliefs of mental health professionals with the 
state of research would do well to give consideration to the antecedent variables 
described above. Additionally, when one considers the training and experience of 
front-line treating professionals, it is reasonable to assume that empirical data 
would have significant impact in any presentation that is designed to change their 
thinking. While heuristic factors should have some relevance for such an 
audience, one would hypothesize that systemic factors, such as research data, may 
well exert an even more powerful influence. That is because most mental health 
practitioners (psychologists, counselors, clinical social workers, etc.) have 
training histories in which research was emphasized, at least to some extent. 
Heuristic factors and non-empirical cultural phenomena, such as ubiquitous 
advertisements for medications, reach everyone including professionals. 
Nevertheless, the role of empirical data in changing thinking ought to be 
particularly important to practitioners whose training has placed emphasis upon 
research. As well, the literature supports the notion that evidence enhances 
changes in thinking (Perloff, 1993; Reinard, 1988).  
It is possible, however, that evidence may be misperceived, or may not be 
“evidence” at all. For example, when pseudo-scientific messages are employed, 
particularly those that contain a great deal of scientific jargon, message 
persuasiveness is enhanced (Haard, Slater, & Long, 2004). That may explain why 
drug industry advertising is sufficiently persuasive that industry profits have 
mushroomed. Nevertheless, it is clear that research evidence is an important 
variable in the influence process. That should be particularly the case when the 
audience is trained to appreciate and utilize research, although one would still 
expect a professional audience to be influenced to some extent by heuristic 
variables.  
Audiences tend to pay greater attention when the speaker’s message has high 
relevance for them. For example, when students listened to a presentation about 
potential changes in comprehensive exams, the message had greater impact if the 
proposed changes would affect their exams, as opposed to exams of some future 
generation of students (Kerr, 2002). Similarity (e.g., age, sex) of presenter and 
audience also affects change in attitude, and that factor is most powerful if a 
similarity (e.g., profession) is relevant to the message presented (e.g., Perloff, 
1993). Ultimately, it would seem, an audience of mental health practitioners 
would be influenced by research evidence, as the credibility enhancing effects of 
evidence seem consistent (O’Keefe, 1998; Reynolds & Reynolds, 2002).  
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Several specific factors tend to cause a data-based message to be favorably 
received. One factor appears to be the citation of sources (Fleshler, Ilardo, & 
Demoretcky, 1974; O’Keefe, 1998). The failure to cite relevant sources may 
result in changes in the opposite direction of that predicted by the speaker, and the 
outcome may be even worse if no supporting citations are cited to counter an 
opposing message that is supported (Reynolds & Reynolds, 2002). Thus, it is not 
surprising that pharmaceutical industry advertising frequently cites “doctors” and 
“researchers.” 
Whether anecdotes help or harm a speaker’s efforts to bring about changed 
thinking within the audience may depend on several factors. Some research 
suggests that anecdotes may be as persuasive as statistical data when the audience 
is only moderately involved (Baesler, 1997). Other data indicate the superiority of 
data over anecdote (Allen & Preiss, 1997). Some research has suggested that 
statistical evidence is better at producing desired knowledge in the listener, while 
anecdotes result in greater affective change (Kopfman, Smith, Ah Yun, and 
Hodges, 1998). In training professionals it probably is wise to employ both 
statistical evidence and anecdote, with the preponderance going to statistical 
evidence, in any effort to bring about attitude/belief change. 
Whether the listener finds the evidence to be valid may also depend upon his 
or her prior knowledge of the subject. Evidence is unlikely to have impact upon 
an audience that lacks prior information about the topic (Reynolds & Reynolds, 
2002). Perhaps that is because an audience must perceive the evidence as 
legitimate, and it may be difficult for that to occur with a naïve audience. An 
audience must be able to follow a link from evidence evaluation to overall 
message evaluation, to a change in acceptance (Reynolds, 1986/1987).  
Another factor known to influence a listener is the perception of bias in the 
presentation. At least a few statements that are at odds with the speaker’s evident 
bias tend to result in greater credibility of the speaker (e.g., McCroskey, 1969). 
However, a speaker walks a fine line in that regard. Once a source is seen as 
invalid on one bit if information, his or her credibility may be weakened on other 
information (Schul & Mayo, 1999). Some research has shown that audience 
members whose initial position is in agreement with the speaker prefer statistical 
evidence, while those who oppose the position advanced by the speaker find 
anecdotal stories to be more persuasive (Slater & Rouner, 1996). 
A look at the audience reactions to U.S. presidential candidates engaged in 
debates revealed that it is possible to present too much information. However, the 
authors acknowledged that such candidates are probably already expected to have 
a great deal of knowledge and to be quick to bring forth that knowledge. 
MIDKIFF & WYATT 
52 
Candidates likely had more credibility to lose than to gain, a fact which may have 
accounted for the effect in their study (Lavasseur & Dean, 1996).  
Thus, the literature suggests that members of a relatively sophisticated 
audience, such as professional mental health practitioners who are unlikely to 
enroll in a full semester’s academic course, would be most amenable to a change 
in their thinking during a brief training program under several specific conditions. 
The speaker should present material in a relatively fluent manner, using a 
“socially powerful” verbal style. The presentation should be primarily supported 
by data, with citations, and should minimize use of anecdotes. The message must 
be seen as highly relevant by the audience and some mention should be made of 
information that goes against the presenter’s evident perspective. Finally, the 
presenter is careful to avoid data overkill. 
Selection of Training Program Content: Rise of the Biological Model 
A brief training program could well employ the techniques described above 
as it addresses issues of social importance. One such issue is the increasing 
tendency toward biological conceptualizations of common disorders and 
medications as the preferred treatment modality. Such training should be 
important to all practitioners, but might resonate particularly well with non-
medical personnel. Of special interest is the extent to which non-medical 
practitioners accept various facets of the biological model as valid, and whether 
brief training would alter their thinking. Although it is not the purpose of this 
article to thoroughly review the topic here, as that is a task that surely would 
consume a number of articles, several of the more salient issues are presented 
below. 
 The gap between what is known about biological causation of common 
disorders and what is sometimes claimed may be illustrated by findings involving 
the neurotransmitter serotonin. Although a connection between serotonin and 
depression is frequently seen in pharmaceutical industry advertisements, such 
claims are at odds with the opinions of experts in the study of serotonin and mood 
(Lacasse & Leo, 2005). The absence of evidence caused Wayne Goodman, Chair 
of the Psychopharmacologic Advisory Committee of the U.S. Food and Drug 
Administration, to say that the chemical imbalance theory of depression is a 
“useful metaphor” but one which should not be employed when doctors talk to 
patients (Ross, 2008). 
In contrast to the drug industry’s marketing claims of the era, in the late 
1990s and early 2000s many academic sources continued to employ substantial 
caution when the causes of common disorders were discussed, as several 
representative examples make clear. Chapter two of an extensive report (U. S. 
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Department of Health and Human Services, 1999) by then Surgeon General David 
Satcher began, “The precise causes of mental disorders are not known” (p. 49). 
Similarly, the Introductory Textbook of Psychiatry (Andreason & Black, 2001) 
stated, “Much of the current investigative research in psychiatry is directed 
toward the goal of identifying the pathophysiology and etiology of major mental 
illnesses, but this goal has been achieved for only a few disorders…” (p. 23). The 
Textbook of Clinical Psychiatry (Hales & Yodofsky, 2003) cautiously noted, 
“Although reliable criteria have been constructed for many psychiatric disorders, 
validation of the diagnostic categories as specific entities has not been 
established” (p. 43). At odds with those careful statements, the medical director of 
the American Psychiatric Association claimed publicly that the same three 
sources had provided powerful evidence in support of biological causation for the 
majority of disorders (MindFreedom, 2003).  
A phenomenon driving the debate about causality is that the current treatment 
of choice for many common disorders is medication. When treating professionals 
and/or clients are convinced that the client’s difficulties in functioning are mostly, 
or completely, biologically caused, they may be poorly motivated to undertake 
non-drug interventions such as those based on a functional analysis of 
environmental variables (Pelham, 2009; Stettin, Yao, Verbrugge, & Aubert, 
2006). Skinner (1956) noted the difficulties that arise when behavior is viewed as 
evidence of an underlying sickness: “It is rare to find behavior dealt with as a 
subject matter in its own right. Instead, it is regarded as evidence for a mental life, 
which is then taken as the primary object of inquiry” (p.84). Replace “mental life” 
with “biological illness” and the contemporary status is relatively well described, 
at least for many individuals.  
The history of the U.S. culture’s turn to biological explanations is intriguing, 
with several identified factors involved. Between 1970 and 1980 the percentage of 
medical school graduates choosing psychiatry as a specialty had dropped by more 
than half, from 11% to 5%. Organized psychiatry then undertook efforts to recruit 
more medical school graduates into the field, and it did so, in part, by advocacy of 
the precept that psychiatry would need to become more “biological,” and thus 
more scientific, if it was to regain lost esteem and influence (Nelson, 1982).  
Also around that time a turf war between psychiatry and what psychiatry saw 
as “intruder” professions intensified psychiatry’s efforts to become more medical. 
Clinical psychologists had initiated efforts to expand their scope of practice to 
include hospital admission privileges (APA Practitioner Focus, 1990), the right to 
be reimbursed by Medicare without supervision by a physician (Buie, 1989), and 
prescription privileges (Seaman, 1997). The fields became embroiled in disputes 
that at times generated visible hostility, and that have continued into the present 
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century (Fox, 2002). A biological worldview tended to buttress psychiatry by 
emphasizing its status as a medical profession.  
The American Psychiatric Association’s response to a recent challenge is of 
interest. The psychiatrists’ guild responded to a challenge by a group of 
professionals and former patients who pressed the doctors’ group to provide 
research evidence in support of biological causation of depression, anxiety and 
other commonly diagnosed disorders. The psychiatric organization’s medical 
director supplied references to various samples of academic literature that, 
ironically, contained relatively weak empirical support for the organization’s 
position, and instead made clear that the causes of most major disorders are 
unknown. When that was pointed out, the psychiatric organization released a 
position statement reasserting its faith in biological causation, but provided no 
supportive evidence (MindFreedom, 2003). 
It has become common to learn of research said to support biological 
causation. However, much of this research has received insufficient critical 
scrutiny. Family studies that seemed to validate genetic contributions, such as 
studies of identical twins who were reared apart, have been plagued by 
methodological and interpretation difficulties. For example, recent examination of 
a table (Gottesman, 1991) that is commonly reproduced in textbooks and articles, 
and which shows elevated risk for schizophrenia based on genetic relatedness, has 
revealed that the table’s pooled results may be parsimoniously explained by 
environmental factors (Joseph & Leo, 2006). Similarly, studies of brain structure 
and functioning, as are done on autopsy or by employment of PET (Positron 
Emission Tomography) and fMRI (functional Magnetic Resonance Imaging) 
scans, have provided vivid images of brain functioning accompanied by 
unwarranted conclusions that biological causes of disorders were on view. 
The twin studies consistently find concordance rates above population 
baselines for most disorders and, thus, have consistently been interpreted to 
provide convincing evidence of at least partial genetic causation. However, 
seldom have twin researchers accounted for the environmental variables that 
might have brought about concordance rates for various disorders. For example, 
even when identical twins are separated soon after birth and reared apart, their 
environments’ responses to their identical levels of physical attractiveness and 
ages at which they reach puberty are routinely ignored or downplayed in the 
literature. Both attractiveness and rate of development, which are identical for 
identical twins regardless of where they are raised, are known to be related to 
emotional and behavioral status. Further, adoption agencies often require that 
adoptive parents match the birth parents with regard to religion, socioeconomic 
station and urban/rural status, variables that also are associated with emotional 
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and behavioral development. Moreover, many sets of identical twins that were 
said to have been reared apart were actually reared in the same extended family, 
according to the twin researchers themselves. Thus, it is likely that identical twins 
reared “apart” may well have been reared in environments that responded to them 
quite similarly, and in ways known to influence behavioral status. Twin 
researchers have usually failed to account for such factors (Joseph & Leo, 2006; 
Midkiff & Wyatt, 2006; Wyatt, 1993; Wyatt, Posey, Welker, & Seamonds, 1984). 
Similar to the issues that confound family and twin studies, research that 
looks at brain structure and functioning via fMRI, PET scans and autopsy may 
easily be misinterpreted. Often the findings are taken as evidence of causation 
when they serve only as evidence of correlation. Although researchers typically 
caution against making causal attributions, the vivid images of brain hot spots, 
oversized ventricles and the like are frequently seen in pharmaceutical industry 
advertising and are presented in ways that tend to reinforce the notion that brain 
events are causal. While at times that may be accurate, as with brain tumors, in 
most cases of depression, anxiety and other common disorders a causal 
connection between unusual brain structure/function and the disorder is cannot be 
shown.  
Related to that, it would be quite surprising if, for example, an individual 
who is experiencing depression had no identifiable changes in brain activity or 
structure. A parsimonious explanation of depressive thoughts, feelings, overt 
behaviors and brain changes may be that the individual has recently experienced 
elevated stressful life circumstances. Alternatively, a person who has not 
undergone such experiences may be depressed because he or she has never 
learned adequate coping skills and is easily overwhelmed by routine levels of 
stress (Wyatt, 2003; Wyatt, 2006). In either event, the brain’s structural and 
functional changes in response to environmental events, termed neuroplasticity, 
have long been documented yet typically de-emphasized in both drug 
advertisements and research reports (Valenstein, 1998). 
Non-empirical events have reinforced the biological model. Quite visible 
among these are the financial interests and advertising practices of the 
pharmaceutical industry. Although recent years have witnessed increasing sales of 
psychotropic medications, a number of meta-analytic reviews have revealed that 
evidence for effectiveness of some medications is relatively weak, a surprising 
finding given the frequency with which medications are prescribed (Khan, 
Leventhal, Khan, & Brown, 2002; Sommers-Flanagan & Sommers-Flanagan, 
1996). A meta-analysis of 19 double-blind studies of top-selling antidepressants 
showed that placebo effects accounted for approximately 75% of the patients’ 
improvement. Moreover, the authors asserted that the remaining 25% 
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improvement could have been the result of an enhanced placebo response due to 
the side effects that patients experience when taking an active drug, or other 
factors (Kirsch & Saperstein, 1998; Kirsch & Weixel, 1988). Similarly, a review 
of 29 published and 11 unpublished studies found that the anti-depressant Paxil 
was better than placebo at improving symptoms of acute, moderate-to-severe 
major depression, but that Paxil’s uncomfortable side effects caused such high 
discontinuation rates that the drug overall is “…not better than placebo…” 
(Lundberg, 2008). 
Busy physicians who prescribe psychotropic medications may be unable to 
keep current on such research. One study revealed that forty percent of primary 
care physicians followed neither long-term medication follow-up guidelines nor 
guidelines for patients who were non-responsive to the medications (Hepner, 
Rowe, Rost, Hickey, Sherbourne, Ford, Meredith, & Rubenstein, 2007). Physi-
cians are routinely targeted by drug makers’ representatives. Sales pitches and 
perks to physicians have become so prevalent that a number of medical schools 
have begun to train students in ways to resist them (Caruso, 2006). Many doctors 
may routinely be misled and may then convey misinformation about causes of 
disorders to their patients. 
 Related to the above, drug study methodology has come under greater 
scrutiny in recent years. For example, methodological concerns regarding the 
placebo run-in or “washout” phase have received increasing attention (Leutcher, 
Cook, Witte, Morgan, & Abrams, 2002; Lydiard, Steiner, Burnham, & Gergel, 
1998; Nierenberg et al., 1995; Londborg, Wolkow, Smith, DuBoff, England, 
Ferguson, Rosenthal, & Weise, 1998; Pohl, Wolkow, & Clary, 1998; Sommers-
Flanagan & Sommers-Flanagan, 1996). A placebo washout phase takes place 
prior to the actual study. All potential subjects are given a one-to-three week 
clinical trial of a placebo. Potential subjects who respond favorably to the placebo 
are then excluded from further participation in the study. Then the remaining 
individuals become the study’s subjects. They are divided into two groups (drug 
v. placebo). Results that suggest a drug effect tend, thus, to be inflated due to the 
intentional exclusion of many placebo responders from the subject pool. When 
studies using the washout methodology, as most studies do, are presented to 
professionals or the public, there is typically little attention to implications of the 
washout phase (Wyatt, 2003). 
Potential over-generalization of drug treatment effects from research 
participants to the general population represents an additional thorny issue. 
Research subjects usually must meet stringent exclusion and inclusion criteria 
and, thus, are less than representative of the population of individuals with 
specific disorders (Khan, Leventhal, Khan, & Brown, 2002). For example, 
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patients are frequently excluded from studies of antidepressants if they: failed to 
respond to any previously prescribed antidepressant during the current episode; 
had another Axis I disorder; experienced any serious medical illness; presented 
with significant lab tests (CBC, urea nitrogen, creatinine, electrolytes, plasma 
glucose, liver function, thyroid, etc); were receiving anticoagulants; had a positive 
drug screen; reported suicidal ideation; ever received CBT or ECT; were pregnant 
or lactating; were women of childbearing potential who were not using 
contraceptives or if they had responded to placebo during the 2-3 week washout 
period (Nierenberg, McLean, Alpert, Worthington, Rosenbaum, & Fava, 1995; 
Zimmerman, Chelminski, & Posternak, 2004). Such exclusions are important and 
protective. However, they tend to limit generalization of the results. 
At times, administrators of managed care programs have argued that 
psychotherapy is "enhancement, not treatment" (Valenstein, 1998). That view 
may be reflected in the fact that, until recent legislation, many health insurance 
plans paid 80 percent of the physician fee, but only 50 percent of the non-
physician psychotherapist's usual fee. Several meta-analyses of studies involving 
thousands of patients have compared medication to non-medical therapies and 
have found that therapy is as effective as medication for treatment of depression 
in the short term, and more effective than medicine in the long term (Jacobson & 
Hollon, 1996; Hollon, 1996; Antonuccio, Danton, & DeNelsky, 1995). While 
such findings enlighten non-medical therapists, the results have yet to generate 
widespread enthusiasm among insurance providers who continue to push for 
biological treatment of presumed biological disorders. 
Financial incentives for the drug industry have contributed to the upswing in 
use of psychotropic medicines over the past thirty years. Prescription of 
psychotropics increased 20% from 1985 to 1994 in the United States. During 
essentially the same period, prescriptions for stimulants tripled and those for 
mood elevators doubled to 20 million (Pincus, Tamielian, Marcus, Olfson, Zarin, 
& Thompson, 1998). In the widely read journal Pediatrics the number of full-
page advertisements for stimulants doubled from 1990 to 2000 (Wyatt, 2003). In 
1996, the year that direct-to-consumer advertising of prescription medications was 
legalized, U. S. patients spent $3.8 billion on anti-depressants. That had nearly 
tripled to $9.9 billion by 2001 (Millenson & Shalowitz, 2005). Many drug 
advertisements suggest, or specifically state, that mental and behavioral disorders 
are “medical illnesses” similar to diabetes or other illnesses, and heavily imply 
that drugs are the treatment of choice. Thus, the pharmaceutical industry’s 
contributions to unwarranted perceptions of biological causation are well known 
(Lacasse & Leo, 2005). 
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Drug researchers’ conflicts of interest (that may have fueled reliance on 
medications and, thus, acceptance of the biological model) gave rise to the 
question, “Is academic medicine for sale?” It was asked by Marcia Angell, then 
Editor-in-Chief of The New England Journal of Medicine. Her question was 
prompted by the fact that many drug researchers have financial links to drug 
companies, links numerous enough among the journal’s authors that Angell 
reported she had insufficient space to list them all in the journal. Moreover, 
Angell postulated that drug companies increasingly promote the creation of 
“diseases” to fit their drugs, and that some among the populace are coming to 
believe they suffer from serious ailments that, perhaps, do not exist (Angell, 
2000). More recently the editor of the Journal of the American Medical 
Association, Catherine DeAngelis, wrote that pharmaceutical companies have so 
much influence that one would have to be “deaf, blind and dumb not to see it….” 
She added that the medical community has “…allowed them to take over, and it’s 
our fault…” (reported in Johnson, 2008). Given this state of affairs, it is difficult 
to rule out the possibility that researchers’ conflicts of interest have played into 
drug makers’ advocacy of the biological model. 
At a glance, the randomized double-blind, placebo controlled studies such as 
those published in the Journal of American Medical Association can appear quite 
convincing, especially when it comes to data on drug efficacy. As one journal 
editor put it, the quality of the journal will bless the quality of the drug (Smith, 
2005). Most professionals trust the peer-reviewed journal as a reliable source of 
information. Those such as Angell and DeAngelis have bluntly raised a concern 
that medical journals are evolving into extensions of the marketing arms of 
pharmaceutical companies (Smith, 2005). A review of eighty-five studies of 
twelve anti-depressants found that 37 of 38 that produced positive results were 
published, while only 3 of 36 with negative results were published and 11 with 
negative or questionable results were written as if the drug had been effective 
(Turner, Matthews, Linardatos, Tell, & Rosenthal, (2008).  
Editors are required to meet budgeting demands, as well as provide scholarly 
articles for professional consumption. Drug companies, except perhaps in rare 
instances, do not attempt crude efforts to “fudge” data. Rather, the pharmaceutical 
industry exerts subtle influence because it underwrites 75% of the studies 
published in many of the major journals such as Annals of Internal Medicine, 
Journal of the American Medical Association, Lancet, and New England Journal 
of Medicine (Smith, 2005). It is reasonable to conclude that such practices can 
create conflicts of interest (Brennan et al., 2006). There have been suggestions 
that drug makers have promoted the over-diagnosis (and possible creation) of 
disorders that their drugs will then treat. For example, in 1994 approximately 
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20,000 U.S. children were diagnosed with bi-polar disorder. That had risen to 
800,000 by 2003, and children’s prescriptions of anti-psychotic medications had 
shown a corresponding increase (Olfson, Blanco, Liu, Moreno, & Laje, 2006). 
The tendency for high-profile physicians to receive income from drug 
companies and then promote those companies’ drugs had reached surprising 
levels by the mid-to-late 2000s. A case in point is that of Dr. Frederick K. 
Goodwin, who was host of PBS’s now-defunct “The Infinite Mind.” On his 
September 20, 2005, radio show Goodwin promoted “…modern treatments—
mood stabilizers in particular—(that) have been proven both safe and effective in 
bipolar children.” The same day, Goodwin was paid $2,500 by Glaxo-Smith-
Kline for his promotional presentation for its mood stabilizer Lamictal. 
Confronted with his evident conflict of interest, Goodwin responded, in part, “…it 
didn’t occur to me that my doing what every other expert in the field does might 
be considered a conflict of interest.” He added, “These (pharmaceutical) 
companies compete with each other and cancel each other out.” Goodwin 
received $329,000 that year from GSK for promoting Lamictal (Harris, 2008).  
One additional variable that tends to reinforce, and is reinforced by, 
medicalization of disorders is the layperson’s preference for the biological model. 
Among the populace, many believe that a psychological explanation implies that a 
person is weak or has not tried to overcome his problem (Link, Struening, Rahav, 
Phelan, & Nuttbrock, 1997; Wahl, 1999). The preference among patients and 
families for a non-stigmatizing, responsibility-shifting view of behavioral 
disorders has been magnified by direct-to-consumer advertising. The downside is 
that the causes of patients’ maladaptive behaviors may be overlooked, at least to 
the extent that the causes are located within patients’ environmental and learning 
histories. 
The Present Study 
The above discussion of the rise of the biological causation model served as 
background for development of a three-hour training program for professionals. 
The present study was an effort to make use of empirically derived training 
strategies in a three-hour program for front-line mental health professionals 
regarding two socially important, treatment-relevant phenomena—the surge of the 
biological causation worldview of mental and behavioral disorders and efficacy of 
drug treatment. This research was designed to explore whether such training 
would change professionals’ views of these two phenomena as they relate to 
common disorders such as depression, anxiety disorders and others. This is 
important because it is likely that, for many professionals, such education is a pre-
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requisite to, although certainly not a guarantee of, corresponding changes in 
clinical practice behaviors. 
Method 
Participants. Participants were 76 mental health professionals and 
paraprofessionals ranging in age from 18 to 63 (see Table 1) who attended a 
three-hour training program.  
Ninety percent of the participants were identified as non-medical mental 
health employees and all were recruited through announcements sent to agencies 
to be posted, and a state psychological association membership flyer about the 
training opportunity, including that continuing education credit was available. 
Credit was not contingent upon pre-post completion of the assessment form. 
The control group consisted of 26 graduate students in a doctoral training 
program in clinical psychology who were enrolled in an advanced statistics class. 
They ranged in age from their twenties to their fifties. Many possessed master’s 
degrees and several had more than ten years of full-time clinical experience at the 
master’s level. Participation was voluntary. The content of the class included no 
components of the training program.  
All subjects in both groups completed an informed consent in accordance 
with the Ethical Principles of Psychologists and Code of Conduct - Principle 6.11.  
Materials. The Strength of Belief Scale (SOBS) is a 38-item survey 
containing six domains of interest to this research: A general biological causation 
domain indicated overall acceptance of the biological causation model for a range 
of mental health problems (anxiety, addiction, depression, ADHD, & 
Schizophrenia). A layperson domain assessed professionals’ perceptions of 
laypersons’ preference for biological explanations. An empirical domain 
examined importance of research findings to professionals regarding causation of 
mental disorders. The pharmaceutical domain looked at the professionals’ 
perceptions of pharmaceutical industry influence upon the rise of the biological 
causation model. A guild domain measured attendees’ views of organized 
psychiatry’s promulgation of biological causation. A health maintenance 
organization (HMO) domain assessed attendees’ views of the insurance industry’s 
preference for the biological model (See Table 2).  
Each of the 38 items was rated on a Likert-type scale of one to six, with 1 
indicating “strongly agree” and 6 indicating “strongly disagree”. The intervening 
points on the Likert scale were agree (2); somewhat agree (3); somewhat disagree 
(4) and disagree (5). 
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Table 1. Participants 
 Frequency Percent 
Age:   
18-26 2 2.6 
27-35 14 18.4 
36-44 8 10.5 
45-53 25 32.9 
54-62 20 26.3 
63+ 7 9.2 
Total 76 100.0 
   
Education:   
High school 2 2.6 
Associate degree 2 2.6 
Bachelor’s degree 13 17.1 
Master’s degree 31 40.8 
Doctoral degree 28 36.8 
   
Discipline:   
Psychologist 45 59.2 
Social Worker 11 14.5 
Counselor 12 15.8 
Other 8 10.5 
   
Employment:   
Community mental health 7 9.2 
State hospital 2 2.6 
Private practice 28 36.8 
General hospital 2 2.6 
For profit psychiatric hospital 11 14.5 
University 6 7.9 
Other 20 26.3 
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Table 2. Strength of Belief Scale (SOBS) items. Participants responded to each 
item on a scale from (1) strongly agree to (6) strongly disagree. 
 
1. Attending pharmaceutical company sponsored workshops is helpful for me to 
understand the benefits of psychotropic medication. (P) 
2. Anxiety is a biological disorder. (B) 
3. In studies of effectiveness of psychotropic drugs, the people who take the 
experimental drugs are representative of the general population. (E) 
4. Medication is less costly than psychotherapy in the eyes of Health Maintenance 
Organizations (HMO) and other health insurance agencies. (H) 
5. Doctors are experts. (L) 
6. Most people in America think that a diagnosis of a mental disorder implies that a 
person is weak. (L) 
7. Family physicians acquire their practical knowledge about psychotropic 
medication from the pharmaceutical company representatives. (P) 
8. A mental illness believed to be biologically caused offers greater hope for 
recovery than non-biologically caused mental illness. (L) 
9. Health Maintenance organizations (HMO) and other health insurance agencies 
limit coverage of the number of psychotherapy sessions much more so than the 
number of office visits for medication refills. (H) 
10. Social workers are well suited to diagnose and treat mental disorders. (G) 
11. Financial interests of pharmaceutical companies have brought about unverified 
claims of causation of mental disorders. (P) 
12. Medical doctors are figures of authority. (G) 
13. Unipolar depression is a biological disorder. (B) 
14. Studies of identical twins who were separated soon after birth and reared apart 
show fairly high levels of concordance for various mental and behavioral 
disorders. (Concordance means if one twin develops a disorder such as 
depression or schizophrenia later in life, then the other develops it too.) (E) 
15. Studies have shown that people with psychological problems have more or less 
of certain brain chemicals called neurotransmitters. (E) 
16. Most people in America think that a diagnosis of a mental illness implies a 
person has not tried to overcome his or her problem. (L) 
17. Pharmaceutical company television advertisements for psychotropic medications 
are believable. (P) 
18. Health Maintenance Organizations (HMO) and other health insurance agencies 
put the patient first. (H) 
19. Medical doctors should be believed. (G) 
20. Psychiatrists are well suited to diagnose and treat mental disorders. (G) 
21. ADHD is a biological disorder. (B) 
22. The majority of mental disorders are biological illnesses rather than the result of 
poorly learned coping skills. (B) 
23. Schizophrenia is a biological disorder. (B) 
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24. Psychologists are well suited to diagnose and treat mental disorders. (G) 
25. Most of my knowledge about psychotropic medication comes from 
pharmaceutical company representatives. (P) 
26. Studies of identical twins who were separated soon after birth and reared apart 
that show fairly higher levels of concordance for various mental and behavioral 
disorders provide strong evidence for biological causation of mental disorders. 
(E) 
27. Counselors are well suited to diagnose and treat mental disorders. (G) 
28. Psychiatrists acquire a significant amount of their practical knowledge about 
psychotropic medication from the pharmaceutical company representatives. (P) 
29. Addiction is a biological disorder. (B) 
30. It is important to listen to those of authority. (G) 
31. There is evidence that biological abnormalities such as chemical imbalances, 
brain lesions or genetic abnormalities cause most mental disorders. (E) 
32. When depressed patients are given an antidepressant a large percentage of the 
patients’ improvement is due to the placebo effect. (E) 
33. Asking my doctor about medications advertised on television can be helpful in 
finding the right medication that will meet my needs. (P) 
34. If in the future scientists identify a specific gene that predisposes people to 
become mentally ill, this would prove that mental illness is a disease. (E) 
35. Studies that show people with psychological problems have more or less of 
certain brain chemicals provide strong evidence for biological causation of 
mental disorders. (E) 
36. I trust that the medication prescribed to me by my doctor is what I need. (G) 
37. If an expert said so, it must be true. (L) 
38. The majority of mental disorders are biological illnesses rather than habit 
disorders. (B) 
Letters in parentheses indicate the domain to which the item belongs: (B)=Biological; 
(L)=Layperson preference; (E)=Empirical; (P)=Pharmaceutical influence; (G)=Guild influence; 
(H)=HMO. 
 
The SOBS was developed in three steps. First, an initial set of items was 
formulated based on intuitive judgment. They were submitted to members of a 
university department of psychology faculty for feedback, which consisted mainly 
of suggestions for editing along with intuitive perceptions of item relevance to the 
study’s goals. After those adjustments were made, the revised surveys were 
completed by a sample of advanced doctoral students. Items that correlated 
weakly with other items within their specified domains were eliminated. A final 
reliability analysis was conducted with the remaining thirty-eight items from the 
treatment group data. Coefficient alphas ranged from .57 - .87 for the six 
domains. (See Table 3.) 
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Table 3. Reliability Analysis of Each Domain 
Domain α 
Biological Domain 
Layperson Domain 
.73 
.76 
Empirical Domain 
Pharmaceutical Domain 
.77 
.82 
Guild Domain 
HMO Domain 
.87 
.57 
 
α = coefficient alpha  
 
Design and procedure.  
Educational Program. A 3-hr training program was developed. Following 
much of the background information described above, it presented the historical 
roots of the rise of the biological causation model and reviewed research often 
cited in support of biological causation. Drug trial methodology and drug 
effectiveness issues were presented, as well. The training was conducted in 
didactic style by the second author who employed 90 power point slides (See 
Table 4.) 
It is of concern that the study’s second author also served as trainer. Several 
procedures were installed to buffer possible presentation bias. At the outset the 
presenter articulated a number of disorders that research has shown to have entire, 
or very heavy, bases in biology. They included Down’s syndrome and disorders 
due to tumor, endocrine dysfunction, known toxins, neurological damage 
resulting from substance abuse and others. Additionally, the presenter stated that 
an unknown percentage of cases of common disorders such as depression and 
anxiety likely have biological roots. Further, the American Psychiatric 
Association’s pro-biological point of view, as put forth in its response to the 
MindFreedom (2003) challenge, was presented. Perhaps most important, the 
program focused on research and encouraged attendee participation in discussion 
of it. Finally, the presenter invited audience responses at any time during the 
presentation. It is thought that possibility of biased presentation was minimized by 
these procedures. 
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Table 4. Outline, goals and objectives of the three-hour training program for 
mental health professionals 
Outline 
• Introduction and cautions: Some disorders are heavily biologically influenced. 
• Dilemmas in treatment. 
• When the patient’s conceptualization is biological, and wrong. 
• Non-empirical influences on patients’ and professionals’ thinking. 
 Medical Guilds. 
 HMO/Insurance Industry. 
 Pharmaceutical companies. 
 The patient’s worldview. 
• Critical thinking for the professional.  What the research tells us. 
 Genetic studies. 
 Studies of brain structure and functioning. 
 The disease model of addiction. 
 ADHD: The food additive and sugar connections. 
• Putting our knowledge to use with patients. 
 
Goals and Objectives 
• Attendees will explore the research on biological causation of abnormal 
behavior. 
• Attendees will understand, and be able to articulate, the influences that lead 
patients and professionals to adopt a biological causation worldview. 
• Attendees will be able to critically evaluate the research on genetic studies, twin 
studies and studies of brain structure and function. 
 
 
 
The treatment group participated in the training program. Prior to the 
beginning of the training the participants were asked to complete the 38-item 
SOBS. Upon completion of the training, participants were asked to again 
complete the SOBS, which contained the same items as the pre-training form, 
with the items randomly reordered.  
A quasi-experimental non-equivalent groups design was utilized. Paired t-
tests (two-tailed) were used to test for pre-post changes within each group 
separately. A linear regression analysis was conducted to evaluate whether a 
change in perceptions regarding the domains (guild; pharmaceutical; layperson; 
HMO/insurance; empirical) was associated with changes in belief in the 
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biological causation domain, after controlling for the effect of several 
demographic variables.  
Results 
Paired sample t-tests were conducted to evaluate whether participants showed 
general change in reported strength of belief in biological causation of several 
mental health disorders (ADHD, anxiety, depression, substance abuse, and 
schizophrenia). The results indicated that, prior to the training, participants tended 
toward agreement with the biological causation model of those disorders, and that 
a post-training a shift toward disagreement had occurred (Mpre = 3.02, SD = .77) 
(Mpost = 3.86, SD = .88), t (75) = 9.48, p = <.001. The standardized effect size 
index, d, was 1.09, (See Table 5). 
A paired sample t-test was also conducted to evaluate whether the training 
changed the professionals’ opinions regarding the remaining four domains 
(pharmaceutical, empirical, layperson, and guild). Mean ratings on the eight items 
in the Empirical Domain were significantly changed from pre-training (Mpre = 
3.29, SD = .74) to post-training (Mpost = 4.0, SD = .76), t (75) = 9.79, p = <.001. 
Essentially, prior to training, participants felt that there was sufficient empirical 
evidence to support a biological causation model for most common abnormal 
behaviors but, post-training, there had been a shift toward disagreement. 
There was also significant decline noted in the attendees’ faith in the claims 
made by the pharmaceutical industry pre- (Mpre = 4.0, SD = .69) to post-
intervention (Mpost = 4.4, SD = .69), t (75) = 6.92, p = <.001. A modest increase in 
skepticism regarding the psychiatric/medical guild’s claims of biological 
causation resulted as well (Mpre = 3.1, SD = .69) (Mpost = 3.2, SD = .71), t (75) = 
3.06, p = <.01.  
A final set of paired sample t-tests was conducted to evaluate whether 
participants in the control group showed any pre-post change. Results indicated 
that no change occurred on any domain.  
A standard multiple regression was performed between the pre-post 
difference in strength of belief in the biological domain, as the dependent 
variable, and the pre-post difference in strength of the pharmaceutical domain, 
empirical domain, and guild domain as the independent variables. The HMO and 
Layperson Domain were excluded from further evaluation, given that Pearson 
correlations were found to be insignificant. Additional analysis included a 
hierarchical regression in which the demographic variables of sex, age, and 
education were controlled for prior to assessing the relationship between the pre-
post difference in strength of belief with the biological domain as the dependent 
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Table 5. Pre and Post Training Means of Treatment Group 
Domain Mpre Mpost Mdiff SDdiff 
Biological Domain 3.02 3.86 -.83** .8 
Layperson Domain 3.4 3.5 -.1 .6 
Empirical Domain 3.3 4.0 -.7** .7 
Pharmaceutical Domain 4.0 4.4 -.44** .55 
Guild Domain 3.1 3.2 -.2* .5 
HMO Domain 3.2 3.1 .2 .7 
Mpre = pretest mean 
Mpost  = posttest mean 
Mdiff  = Mpre - Mpost 
SDdiff  = standard deviation of Mdiff 
d = Cohen’s measure of effect size 
*p < .01 
**p < .001 
 
variable and the pre-post differences in strength of belief with the pharmaceutical 
domain, empirical domain, and guild domain as the independent variables. 
Table 6 displays the results for the regression analyses. R for regression was 
significantly different from zero: R2 = .340, F(3, 72) = 12.377, p < .001. The 
combination of the three independent variables contributed significantly to 
prediction of strength of belief in biological causation. Upon closer review of the 
regression coefficients it seems that of the three variables, empirical domain had 
the greatest influence. Age, sex, and education as predictors for strength of belief 
in the biological domain were not significant, R2 = .053, F(3, 72) = 1.348, p = 
.266. After controlling for these demographic variables, the three domains still 
accounted for a significant proportion of variability ∆ R2 = .350, F(3, 69) = 13.49, 
p < .001 . 
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Table 6. Standard Multiple Regression of Guild, Empirical & Pharmaceutical 
Influences on the Strength of Belief (SOB) in Biological Causation 
 
Variables 
SOB 
BDMN 
DV 
G-INF E-INF P-INF B β 
G-INF .355    .216 .137 
E-INF .530 .409   .464** .396 
P-INF 
 .395 .271 .380  .288 .207 
MEANS .8302 .1702 .7319 .4359   
STANDARD 
DEVIATIONS .76367 .48437 .65137 .54921 
R2 =.340 
Adjusted   R2 =.313 
R =.583** 
*p < .01 
**p < .001 
SOB = Strength of Belief Scale 
BDMN = Biological Domain 
G-INF = Guild Influence 
E-INF = Empirical Influence 
P-INF = Pharmaceutical Influence 
Numbers  = Pearson Correlations 
 
Discussion 
This study examined whether a three-hour, data-based continuing education 
training program that employed established antecedent methodology would altar 
practicing mental health professionals’ perceptions of causation and drug 
treatment. A three-hour time frame was chosen because practicing professionals 
typically obtain continuing education by attending half-day training sessions and 
are unlikely to enroll in full-semester graduate courses. The study looked at the 
extent to which attendees, pre- and post-training, accepted a biological causation 
worldview both generally and for several common disorders including ADHD, 
unipolar depression, anxiety disorders, and schizophrenia.  
The presentation employed several variables that the literature suggests are 
most effective with a relatively sophisticated audience. The speaker was 
reasonably well-known to the audience (university professor in a relatively small 
state), well organized and presented the training fluently. He used data and cited 
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sources. He was alert to the notion that data overkill can drain a presentation of its 
impact. He avoided anecdote, although attendees occasionally described anec-
dotes about their clients.  
The literature suggests that such an audience will respond favorably to some 
evidence that goes against the general thrust of a presentation. Several facets of 
the training were included to insure both that this was accomplished and, as 
important, that the presentation was indeed balanced. For example, the presenter 
stated that some disorders are caused biologically, and listed a number of them. 
The training included the American Psychiatric Association’s defense of 
biological causation, and other elements that were thought to serve as buffers 
against bias. Representative research usually cited in support of biological 
causation was examined. The historical roots of the ascendance of the model and 
the dovetailing of interests of organized psychiatry and the pharmaceutical 
industry and related topics, were presented. 
The program’s critique of studies that are often cited as evidence of 
biological causation, such as studies of identical twins reared apart and studies of 
brain structure, function and chemistry, resonated particularly well with the 
attendees, given the significant pre-to-post change in the empirical domain. That 
finding is consistent with the systemic view (the listener is alert, responding to 
facts) described above. This becomes particularly important when one considers 
that the change occurred in experienced professionals, individuals whom one 
might suppose had become somewhat inured against substantial world-view 
changes. That the training was relatively brief adds to the importance of the 
results because, unlike a full-semester graduate course which most practitioners 
would be unlikely to pursue, professionals most often obtain continuing education 
in half-day segments.  
Exploration of the connection between the financial interests of the 
pharmaceutical industry and the growth of the biological causation model, 
although factually presented, may have reached attendees somewhat more 
heuristically or emotionally. Participants came to the training with some degree of 
conviction that the financial interests of drug companies have brought about 
unverified claims of both causation and drug effectiveness. However, the brief 
review of that topic strengthened attendees’ pre-existing skepticism.  
It took minimal time to present methodological issues (the washout phase, 
representativeness of study participants, power of the placebo) and interpretative 
difficulties in studies of drug effectiveness. Nevertheless, that portion of the 
training produced change in attendees’ thinking as well.  
Thus, the study’s findings are consistent with the hypothesis that a brief, 
research-based training program could alter the perceptions of active 
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professionals regarding topics of importance in treatment settings—the causes and 
treatment of common abnormal behaviors.  
An issue in interpretation of the results is that our conceptualization of 
causation as either “biological” or “not biological” leaves open the question of 
contributions of both biology and environment, a perspective that no doubt 
accounts for an unknown percentage of various disorders. However, it was the 
intent of this research to discover whether the training would alter mental health 
professionals’ worldviews. Thus, participants were required to choose something 
other than a convenient mid-point. 
Another concern arises when considering the presentation of data and 
inferred change as a result of such presentation. It is difficult to extract the 
influence of expert power (factual information provided by a skilled presenter) 
from prestige or referent power (well known professor and likeable figure) when 
inferring subjects’ responses to items (French & Raven, 1959, Aronson & Golden, 
1962; Berlo, Lemest, & Martin, 1969; Haughtvedt, 1997). Therefore, left open to 
some speculation is the question: Was it the message or the messenger that 
brought about change? The answer is well beyond the scope of the present study. 
However, it is important that it was the “package” of expert presenter, data, 
source citations, historic review and the like that was effective. The conundrum is 
that, with an esoteric topic and a professional audience, it is difficult to imagine a 
credible presentation by an unknown individual with minimal, or no, credentials.  
 Another consideration lies in the measuring of change and what it means 
to the individual professional. It is unknown how a unit of change in a 
psychometric measure such as the SOBS might relate to a change, if any, in 
practice (Blanton & Jaccard, 2006). We made no assumptions that changed 
attitudes would be stable or that they would necessarily result in changes in 
clinicians’ practices. Those are topics of future research. Rather, our assumption 
is that the present study has established a platform on which changed practice 
habits may be built. Without an enhanced, data-based change in thinking about 
causation, it probably would be quite difficult to bring about changed techniques 
in clinical practice.  
A number of attendees informally remarked that the training had opened their 
eyes to research issues that they had not considered and which had not been 
addressed in their graduate training. Others pointed out that they had already felt 
skepticism about claims of drug companies, but that the training helped them gain 
focus on the specifics. Still others commented that the guild interests of organized 
psychiatry were not new to them, but that they had been unaware of the extent to 
which those interests had become symbiotic with drug industry interests.  
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The informal comments were reflected in several items whose mean ratings 
changed a full point, or nearly so, on the six-point SOBS scale. These included 
items dealing with causes of several disorders (items 13, 21 and 23, Table 2) and 
items dealing with the methodological and interpretive puzzles in research 
looking at identical twins reared apart (items 14 and 26) and of brain chemistry 
and structure (item 35). Critical examination of pharmaceutical industry influence 
also was reflected in substantial change in the skeptical direction (item 1). 
Aside from providing a training model, the program’s content suggests a 
likely need for more public funding of trials, particularly of large head-to-head 
trials of all treatments available for a given disorder. A federally regulated 
website could house the studies. Journal editors might then concentrate on 
critically describing the studies, instead of suffering the financial slings of staying 
in publication (Smith, 2005).  
The professional cultures would also do well to re-orient both themselves and 
the populace as to what is, and is not, known about the causes of abnormal 
behavior. Authors of textbooks, such as those that likely were read by the 
professional participants in this study during their training, should revise their 
books’ sections that deal with causation so that they offer in-depth, critical 
analyses of data such as those presented in the present training program. Our 
informal reviews of a number of frequently adopted textbooks revealed few that 
approach that goal and none that, in our view, achieve it. 
There are other content-related suggestions that arise from the three-hour 
program’s results. Textbook authors and university professors would do well to 
address cultural influences, such as direct-to-consumer advertising and 
advertising to physicians. When a consumer responds to an ask-your-doctor 
commercial, probability of prescription of that medication rises dramatically, even 
when the patient presents with minor symptoms (Kravitz, Epstein, Feldman, 
Franz, Rahman, Wilkes, Ladson, & Franks, 2005). The Food and Drug 
Administration (FDA) would do well to move more forcefully to replace drug 
company “education” with scientifically based information that will stimulate 
better conversations between doctors and patients. 
Physician education on several issues should be enhanced. For example, 
physicians often cannot distinguish true statements from false ones when they 
listen to sales pitches (Hopper, Speece, & Musial, 1990). Many physicians would 
benefit from enhanced awareness of the impact of gifts, as the majority of them 
feel that gifts given by pharmaceutical representatives do not influence their own 
prescribing practices, but that such gifts do influence their colleagues (Steinman, 
2000; Steinman, Shlipak, & McPhee, 2000).  
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It is possible that improved government regulation of the claims made by the 
drug industry, mass media organizations, and physicians’ groups may be of help, 
although that task may well be very difficult. The Food and Drug administration’s 
2007 Science Board report detailed difficulties with inadequate staffing, poor 
retention of staff, out-of-date technology and a general lack of resources at the 
FDA (FDA Science and Mission at Risk, 2007).  
Undertaking a paradigm shift is a daunting task, given the financial resources 
available to the pharmaceutical industry and to organized medicine. However, 
given that a three-hour continuing education program, carefully employing 
established antecedent teaching techniques, was able to bring about significant 
change, large funding sources such as the National Institute of Mental Health may 
yet be convinced to more vigorously support enhancement of empirically derived 
understanding of mental health syndromes and treatment. 
Although it was not this study’s purpose to resolve the debate about 
etiological bases of behavior and treatment practices, this research provides a 
basis for extension of the debate. This was an effort to determine whether the 
thinking of professionals would be changed significantly as regards practice 
related topics, within the confines of a brief continuing education program. That 
goal was achieved. Such enhanced understanding would seem to be a prerequisite 
if non-drug interventions such as applied behavior analysis are to flourish.  
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